Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedOpen accessInfluenzaH5N1

Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice

npj Vaccines·

Kelly Pyles, Tamarand L. Darling, Lin-Chen Huang, Mimi Guebre-Xabier, Melinda Hersey, Ann M. Greene, Nita Patel, Gale Smith, Adrianus C. M. Boon

DOI
10.1038/s41541-026-01523-8
PMID
42431930
PMCID
OpenAlex
W7167935461
Study type
Journal article
Publisher
Springer Science and Business Media LLC
Article type
journal-article
Integrity
current

Why this research matters now

The data indicate that this adjuvanted nanoparticle approach may circumvent interference from existing seasonal influenza antibodies, highlighting its potential utility in pandemic response strategies.

01

Structured evidence summary

Research question

The investigation evaluates whether a Matrix-M-adjuvanted nanoparticle vaccine can generate protective immune responses against an emerging H5N1 strain when delivered via nasal or injection routes.

Study design

A controlled animal experiment utilizing two mouse cohorts, one unexposed and one previously administered a seasonal influenza formulation, followed by targeted viral challenge.

Population and setting

Laboratory mice subjected to either baseline conditions or prior seasonal influenza immunization before receiving the experimental nanoparticle construct.

Main findings

Both delivery methods triggered substantial antibody production and prevented mortality following lethal exposure. Previously immunized animals required only a single booster dose to achieve comparable defense, while nasal application resulted in lower viral detection within the upper respiratory tract compared to injections.

Public-health relevance

The data indicate that this adjuvanted nanoparticle approach may circumvent interference from existing seasonal influenza antibodies, highlighting its potential utility in pandemic response strategies.

Important limitations

Findings are restricted to murine models and do not account for human physiological differences, extended durability of protection, or adverse event profiling.

GIDS interpretation

This record documents early-stage experimental work on a specific adjuvanted platform targeting an evolving avian influenza lineage, offering contextual background for monitoring vaccine innovation trajectories rather than active epidemiological tracking.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 9 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseabout diseaseaddresses topicaddresses topicevaluates interventionhas pathogen typestudied population settingstudies pathogenuses study design